Shepherd J, Bicker S, Lorimer A R, Packard C J
J Lipid Res. 1979 Nov;20(8):999-1006.
Binding of human low density lipoproteins (LDL) to their specific receptor on cultured cells can be inhibited by treatment with 1,2-cyclohexanedione which blocks a number of functionally significant arginyl residues on the apolipoprotein. We have used this observation to examine the role of the receptor pathway in LDL catabolism in man. The plasma clearance rates of 125I-LDL and 131I-cyclohexanedione-treated LDL were measured in four normal and four heterozygous familial hypercholesterolemic subjects. Chemical modification of the lipoprotein significantly reduced its fractional clearance rate and permitted calculation of receptor-mediated and receptor independent catabolism in both groups. The normal subjects cleared 11% of their plasma LDL pool (corresponding to 3.0 mg/kg per day) by a receptor-independent path. In tared daily by these pathways, respectively. Because the mean apoLDL pool size in the group was increased 3-fold over normal, this gave absolute clearance rates for the apoprotein of 2.5 mg/kg per day via the receptors and 12.8 mg/kg per day by the nonreceptor pathway. We conclude that the specific LDL receptor mechanism operates in vivo and probably accounts for 33% and 16% of overall LDL catabolism in normal and heterozygous familial hypercholesterolemic subjects, respectively.
用1,2 - 环己二酮处理可抑制人低密度脂蛋白(LDL)与培养细胞上其特异性受体的结合,该试剂可封闭载脂蛋白上许多具有功能意义的精氨酰残基。我们利用这一观察结果来研究受体途径在人体LDL分解代谢中的作用。在4名正常人和4名杂合子家族性高胆固醇血症患者中测量了125I - LDL和经131I - 环己二酮处理的LDL的血浆清除率。脂蛋白的化学修饰显著降低了其分数清除率,并能够计算两组中受体介导和非受体介导的分解代谢。正常受试者通过非受体途径清除其血浆LDL池的11%(相当于每天3.0mg/kg)。在杂合子家族性高胆固醇血症患者中,通过这些途径分别清除26%和74%。由于该组中载脂蛋白LDL池的平均大小比正常增加了3倍,这使得载脂蛋白通过受体途径的绝对清除率为每天2.5mg/kg,通过非受体途径为每天12.8mg/kg。我们得出结论,特异性LDL受体机制在体内起作用,并且可能分别占正常和杂合子家族性高胆固醇血症患者总体LDL分解代谢的33%和16%。